Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 328

1.

Benefits and risks of anticoagulation resumption following traumatic brain injury.

Albrecht JS, Liu X, Baumgarten M, Langenberg P, Rattinger GB, Smith GS, Gambert SR, Gottlieb SS, Zuckerman IH.

JAMA Intern Med. 2014 Aug;174(8):1244-51. doi: 10.1001/jamainternmed.2014.2534.

2.

Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation.

Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK.

Clin J Am Soc Nephrol. 2011 Nov;6(11):2662-8. doi: 10.2215/CJN.04550511.

3.

Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.

Circulation. 2015 Jan 13;131(2):157-64. doi: 10.1161/CIRCULATIONAHA.114.012061.

4.

Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.

Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB.

J Am Coll Cardiol. 2014 May 27;63(20):2141-7. doi: 10.1016/j.jacc.2014.02.549.

5.

Risks and benefits of resumption of anticoagulation following traumatic brain injury remain complex and uncertain.

Grandhi R, Shutter LA, Okonkwo DO.

JAMA Intern Med. 2015 May;175(5):866. doi: 10.1001/jamainternmed.2015.0298. No abstract available.

PMID:
25938318
6.

Risks and benefits of resumption of anticoagulation following traumatic brain injury remain complex and uncertain-reply.

Albrecht JS, Liu X, Zuckerman IH.

JAMA Intern Med. 2015 May;175(5):866-7. doi: 10.1001/jamainternmed.2015.0301. No abstract available.

PMID:
25938319
7.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
8.

The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.

Sengupta N, Feuerstein JD, Patwardhan VR, Tapper EB, Ketwaroo GA, Thaker AM, Leffler DA.

Am J Gastroenterol. 2015 Feb;110(2):328-35. doi: 10.1038/ajg.2014.398. Erratum in: Am J Gastroenterol. 2015 Mar;110(3):480.

PMID:
25512338
9.

Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.

Chan YH, Yen KC, See LC, Chang SH, Wu LS, Lee HF, Tu HT, Yeh YH, Kuo CT.

Stroke. 2016 Feb;47(2):441-9. doi: 10.1161/STROKEAHA.115.011476.

PMID:
26732563
10.

Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study.

Vestergaard AS, Skjøth F, Lip GY, Larsen TB.

Stroke. 2016 Apr;47(4):979-85. doi: 10.1161/STROKEAHA.115.012338.

PMID:
26883499
11.

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.

Renda G, di Nicola M, De Caterina R.

Am J Med. 2015 Sep;128(9):1007-14.e2. doi: 10.1016/j.amjmed.2015.03.034.

PMID:
25910790
12.

The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.

Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ.

J Manag Care Pharm. 2013 May;19(4):302-16.

13.

A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.

Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, Schwartzman E.

Thromb Haemost. 2015 Nov 25;114(6):1290-8. doi: 10.1160/TH15-06-0453.

PMID:
26446456
14.

Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin.

Dogliotti A, Paolasso E, Giugliano RP.

Clin Cardiol. 2013 Feb;36(2):61-7. doi: 10.1002/clc.22081. Review.

15.

Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran.

Vaughan Sarrazin MS, Jones M, Mazur A, Chrischilles E, Cram P.

Am J Med. 2014 Dec;127(12):1179-85. doi: 10.1016/j.amjmed.2014.07.024.

PMID:
25107386
16.

Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study.

Seet RC, Rabinstein AA, Christianson TJ, Petty GW, Brown RD Jr.

J Stroke Cerebrovasc Dis. 2013 May;22(4):561-9. doi: 10.1016/j.jstrokecerebrovasdis.2013.01.019.

18.

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators..

Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.

PMID:
22084332
19.

Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.

Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, Stenvinkel P, Jacobson SH, Jernberg T.

JAMA. 2014 Mar 5;311(9):919-28. doi: 10.1001/jama.2014.1334.

PMID:
24595776
20.

The net clinical benefit of warfarin anticoagulation in atrial fibrillation.

Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS.

Ann Intern Med. 2009 Sep 1;151(5):297-305.

Items per page

Supplemental Content

Support Center